Approximately 10 per cent of newborn babies require some form of resuscitation or stabilisation at birth, which amounts to 80,000 babies born each year in the UK and approximately 14 million per year globally. Newborn babies who do not receive the necessary interventions quickly and efficiently are at risk of both overtreatment and undertreatment, and the baby’s heart rate is the key driver of optimal medical care and interventions
The SurePulse VS device allows the delivery team to see, wirelessly, an accurate and reliable heart rate in real time. This is in contrast to current alternatives where heart rate monitoring in the all-important first few minutes of a baby’s life is intermittent, and the stethoscope, electrocardiogram and wrist-mounted pulse oximeter all have limitations.
SurePulse VS has the potential to become the new standard of care globally for newborn babies requiring resuscitation.
Says Claire Clayton: “Working with SurePulse Medical has been a truly enlightening experience and it’s extremely exciting to be working with a company which is operating at the cutting edge of developments in potentially life saving technology. So far we have provided all new photography, exhibition stand and printed marketing materials and we look forward to continuing our working relationship into the future.”
Says James Carpenter, CEO of SurePulse: “We are delighted with the work that Claire and John have done for us. They are highly professional and nothing is too much trouble. We look forward to working on a number of future projects with them.”